Filtered By:
Cancer: Lung Cancer
This page shows you your search results in order of date. This is page number 10.
Order by Relevance | Date
Total 1667 results found since Jan 2013.
Exosomal FZD10 derived from non-small cell lung cancer cells promotes angiogenesis of human umbilical venous endothelial cells < em > in vitro < /em >
CONCLUSION: Exosomal FZD10 derived from NSCLC cells promotes HUVEC angiogenesis in vitro, the mechanism of which may involve the activation of PI3K and Erk1/2 signaling pathways.PMID:36210708 | PMC:PMC9550558 | DOI:10.12122/j.issn.1673-4254.2022.09.11
Source: Journal of Southern Medical University - October 10, 2022 Category: Universities & Medical Training Authors: X Wu R Zhan D Cheng L Chen T Wang X Tang Source Type: research
MHY4571, a novel diarylcyclohexanone derivative, exerts anti-cancer activity by regulating the PKA-cAMP-response element-binding protein pathway in squamous cell lung cancer
ConclusionsOur results imply that MHY4571 may be a potential drug candidate for squamous cell lung cancer treatment.
Source: Experimental Hematology and Oncology - October 8, 2022 Category: Cancer & Oncology Source Type: research
Gefitinib enhances the anti ‑tumor immune response against EGFR‑mutated NSCLC by upregulating B7H5 expression and activating T cells via CD28H
Int J Oncol. 2022 Dec;61(6):146. doi: 10.3892/ijo.2022.5436. Epub 2022 Oct 7.ABSTRACTGefitinib is a sensitive and effective drug to treat non‑small‑cell lung cancer (NSCLC) carrying the somatic activating mutations of the tyrosine kinase domain of epidermal growth factor receptor (EGFR). In the present study, a new mechanism of action of gefitinib in EGFR‑mutated NSCLC cells was discovered using in vitro co‑culture of NSCLC cells with peripheral blood mononuclear cells (PBMCs). Gefitinib significantly enhanced the cytotoxicity of PBMCs against NSCLC cells expressing mutated EGFR but not in cells expressing wild‑t...
Source: Cancer Control - October 7, 2022 Category: Cancer & Oncology Authors: Huihui Guo Xilin Zhang Shangzhi Xie Tianwei Chen Dong Xie Ying Cai Dawei Cui Liang Wang Wei Chen Xiang Wang Source Type: research
